rare & serious events label comprehension ruth s. day duke university [email protected] fda...
TRANSCRIPT
![Page 1: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/1.jpg)
RARE & SERIOUS EVENTSLabel Comprehension
Ruth S. Day
Duke [email protected]
FDA Arthritis Advisory Committee March 5, 2003
![Page 2: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/2.jpg)
“COGNITIVE ACCESSIBILITY”
The ease with which
people can
findunderstandrememberuse
drug
information
in a safe and effective manner.
![Page 3: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/3.jpg)
COGNITIVE PRINCIPLES
![Page 4: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/4.jpg)
COGNITIVE PRINCIPLES
Information Load
Chunking
Coding
Representation
Location
![Page 5: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/5.jpg)
COGNITIVE PRINCIPLES
Information Load
Chunking
Coding
Representation
Location
Readability
Comprehension
Attention
Cognitive Task
Metacognition
![Page 6: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/6.jpg)
LOAD
How much is too much?
![Page 7: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/7.jpg)
LOAD
Information Load
How much is too much?
![Page 8: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/8.jpg)
LOAD
Information Cognitive Load Load
How much is too much?
![Page 9: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/9.jpg)
POSSIBLE WARNING
![Page 10: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/10.jpg)
POSSIBLE WARNING
“Rare but life-threatening liver toxicity has been reported, including acute liver failure.”
![Page 11: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/11.jpg)
LOCATION ?
![Page 12: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/12.jpg)
LOCATION ?
Black Box Warnings Section
![Page 13: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/13.jpg)
P r e s c r i b i n g I n f o r m a t i o n a s o f A p r i l 2 0 0 0 AA R A V A ™ T a b l e t s( l e f l u n o m i d e )1 0 m g , 2 0 m g , 1 0 0 m g
C O N T R A I N D I C A T I O N S A N D W A R N I N G S
P R E G N A N C Y M U S T B E E X C L U D E D B E F O R E T H E S T A R T O F T R E A T M E N T W I T HA R A V A . A R A V A I S C O N T R A I N D I C A T E D I N P R E G N A N T W O M E N , O R W O M E N O FC H I L D B E A R I N G P O T E N T I A L W H O A R E N O T U S I N G R E L I A B L E C O N T R A C E P T I O N . ( S E EC O N T R A I N D I C A T I O N S A N D W A R N I N G S . ) P R E G N A N C Y M U S T B E A V O I D E D D U R I N GA R A V A T R E A T M E N T O R P R I O R T O T H E C O M P L E T I O N O F T H E D R U G E L I M I N A T I O NP R O C E D U R E A F T E R A R A V A T R E A T M E N T .
D E S C R I P T I O NA R A V A ™ ( l e f l u n o m i d e ) i s a p y r i m i d i n e s y n t h e s i s i n h i b i t o r . T h e c h e m i c a l n a m e f o r l e f l u n o m i d e i sN - ( 4 ´ - t r i f l u o r o m e t h y l p h e n y l ) - 5 - m e t h y l i s o x a z o l e - 4 - c a r b o x a m i d e . I t h a s a n e m p i r i c a l f o r m u l aC 1 2 H 9 F 3 N 2 O 2 , a m o l e c u l a r w e i g h t o f 2 7 0 . 2 a n d t h e f o l l o w i n g s t r u c t u r a l f o r m u l a :
A R A V A i s a v a i l a b l e f o r o r a l a d m i n i s t r a t i o n a s t a b l e t s c o n t a i n i n g 1 0 , 2 0 , o r 1 0 0 m g o f a c t i v e d r u g .C o m b i n e d w i t h l e f l u n o m i d e a r e t h e f o l l o w i n g i n a c t i v e i n g r e d i e n t s : c o l l o i d a l s i l i c o n d i o x i d e ,c r o s p o v i d o n e , h y d r o x y p r o p y l m e t h y l c e l l u l o s e , l a c t o s e m o n o h y d r a t e , m a g n e s i u m s t e a r a t e ,p o l y e t h y l e n e g l y c o l , p o v i d o n e , s t a r c h , t a l c , t i t a n i u m d i o x i d e , a n d y e l l o w f e r r i c o x i d e ( 2 0 m g t a b l e to n l y ) .C L I N I C A L P H A R M A C O L O G YM e c h a n i s m o f A c t i o nL e f l u n o m i d e i s a n i s o x a z o l e i m m u n o m o d u l a t o r y a g e n t w h i c h i n h i b i t s d i h y d r o o r o t a t ed e h y d r o g e n a s e ( a n e n z y m e i n v o l v e d i n d e n o v o p y r i m i d i n e s y n t h e s i s ) a n d h a s a n t i p r o l i f e r a t i v ea c t i v i t y . S e v e r a l i n v i v o a n d i n v i t r o e x p e r i m e n t a l m o d e l s h a v e d e m o n s t r a t e d a n a n t i - i n f l a m m a t o r ye f f e c t .P h a r m a c o k i n e t i c sF o l l o w i n g o r a l a d m i n i s t r a t i o n , l e f l u n o m i d e i s m e t a b o l i z e d t o a n a c t i v e m e t a b o l i t e A 7 7 1 7 2 6( h e r e a f t e r r e f e r r e d t o a s M 1 ) w h i c h i s r e s p o n s i b l e f o r e s s e n t i a l l y a l l o f i t s a c t i v i t y i n v i v o . P l a s m al e v e l s o f l e f l u n o m i d e a r e o c c a s i o n a l l y s e e n , a t v e r y l o w l e v e l s . S t u d i e s o f t h e p h a r m a c o k i n e t i c s o fl e f l u n o m i d e h a v e p r i m a r i l y e x a m i n e d t h e p l a s m a c o n c e n t r a t i o n s o f t h i s a c t i v e m e t a b o l i t e .
A b s o r p t i o nF o l l o w i n g o r a l a d m i n i s t r a t i o n , p e a k l e v e l s o f t h e a c t i v e m e t a b o l i t e , M 1 , o c c u r r e d b e t w e e n 6 - 1 2h o u r s a f t e r d o s i n g . D u e t o t h e v e r y l o n g h a l f - l i f e o f M 1 ( ~ 2 w e e k s ) , a l o a d i n g d o s e o f 1 0 0 m g f o r3 d a y s w a s u s e d i n c l i n i c a l s t u d i e s t o f a c i l i t a t e t h e r a p i d a t t a i n m e n t o f s t e a d y - s t a t e l e v e l s o f M 1 .
BlackBox
![Page 14: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/14.jpg)
When female rats were treated with 1.25 mg/kg of leflunomide beginning 14 days before matingand continuing until the end of lactation, the offspring exhibited marked (greater than 90%)decreases in postnatal survival. The systemic exposure level at 1.25 mg/kg was approximately1/100 the human exposure level based on AUC.ARAVA is contraindicated in women who are or may become pregnant. If this drug is used duringpregnancy, or if the patient becomes pregnant while taking this drug, the patient should beapprised of the potential hazard to the fetus.WARNINGSImmunosuppression PotentialARAVA is not recommended for patients with severe immunodeficiency, bone marrow dysplasia,or severe, uncontrolled infections.There have been rare reports of pancytopenia in patients receiving ARAVA. In most of thesecases, patients received concomitant treatment with methotrexate or other immunosuppressiveagents, or they had recently discontinued these therapies; in some cases, patients had a priorhistory of a significant hematologic abnormality. If ARAVA is used in such patients, it should beadministered with caution and with frequent clinical and hematologic monitoring. The use ofARAVA in combination therapy with methotrexate has not been adequately studied in a controlledsetting.If evidence of bone marrow suppression occurs in a patient taking ARAVA, treatment withARAVA should be stopped, and cholestyramine or charcoal should be used to reduce the plasmaconcentration of leflunomide active metabolite (see PRECAUTIONS – General – Need for DrugElimination).In any situation in which the decision is made to switch from ARAVA to another anti-rheumaticagent with a known potential for hematologic suppression, it would be prudent to monitor forhematologic toxicity, because there will be overlap of systemic exposure to both compounds.ARAVA washout with cholestyramine or charcoal may decrease this risk, but also may inducedisease worsening if the patient had been responding to ARAVA treatment.Skin ReactionsRare cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported inpatients receiving ARAVA. If a patient taking ARAVA develops any of these conditions, ARAVAtherapy should be stopped, and a drug elimination procedure is recommended (seePRECAUTIONS - General - Need for Drug Elimination).HepatotoxicityIn clinical trials, ARAVA treatment was associated with elevations of liver enzymes, primarily ALTand AST, in a significant number of patients; these effects were generally reversible. Mosttransaminase elevations were mild (=2-fold ULN) and usually resolved while continuingtreatment. Marked elevations (>3-fold ULN) occurred infrequently and reversed with dosereduction or discontinuation of treatment. The following table shows liver enzyme elevations seenwith monthly monitoring in clinical trials US301 and MN301. It was notable that the absence offolate use in MN302 was associated with a considerably greater incidence of liver enzymeelevation on methotrexate.
Table 4. Liver Enzyme Elevations >3-fold Upper Limits of Normal (ULN)US301 MN301 MN302*
LEF PL MTX LEF PL SSZ LEF MTXALT (SGPT)
>3-fold ULN 8 3 5 2 1 2 13 83(n %) (4.4) (2.5) (2.7) (1.5) (1.1) (1.5) (2.6) (16.7)
Reversed to =2-fold ULN: 8 3 5 2 1 2 12 82
Warnings
![Page 15: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/15.jpg)
Does it matter?
![Page 16: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/16.jpg)
Study CognitiveLabel Tasks
time
PROCEDURE
![Page 17: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/17.jpg)
Study CognitiveLabel Tasks
time
CONTENT
--Indication
--Warnings (liver failure)
PROCEDURE
![Page 18: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/18.jpg)
Study CognitiveLabel Tasks
time
CONTENT
--Indication
--Warnings (liver failure)
TASKS
--Free Recall
--Recognition
PROCEDURE
![Page 19: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/19.jpg)
CONTRAINDICATIONS AND WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THESTART OF TREATMENT WITH ARAVA. ARAVA ISCONTRAINDICATED IN PREGNANT WOMEN, ORWOMEN OF CHILDBEARING POTENTIAL WHO ARENOT USING RELIABLE CONTRACEPTION. (SEECONTRAINDICATIONS AND WARNINGS.) PREGNANCYMUST BE AVOIDED DURING ARAVA TREATMENT ORPRIOR TO THE COMPLETION OF THE DRUGELIMINATION PROCEDURE AFTER ARAVATREATMENT. RARE BUT LIFE-THREATENING LIVERTOXICITY HAS BEEN REPORTED, INCLUDING ACUTELIVER FAILURE.
WARNINGSHepatotoxicityRare but life-threatening liver toxicity has been reported,including acute liver failure. In clinical trials, ARAVAtreatment was associated with elevations of liver enzymes,primarily ALT and AST, in a significant number of patients;these effects were generally reversible. Most transaminase
elevations were mild (=2-fold ULN) and usually resolvedwhile continuing treatment. Marked elevations (>3-fold ULN)occurred infrequently and reversed with dose reduction ordiscontinuation of treatment. The following table shows liverenzyme elevations seen with monthly monitoring in clinicaltrials US301 and MN301. It was notable that the absence offolate use in MN302 was associated with a considerablygreater incidence of liver enzyme elevation on methotrexate.
![Page 20: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/20.jpg)
0
10
20
30
40
50
% C
OR
RE
CT
FREE RECALL
“What are the warnings?”
![Page 21: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/21.jpg)
0
10
20
30
40
50
% C
OR
RE
CT
FREE RECALL
“What are the warnings?”
![Page 22: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/22.jpg)
0
10
20
30
40
50
% C
OR
RE
CT
FREE RECALL
“What are the warnings?”
2.5x
![Page 23: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/23.jpg)
0102030405060708090
100
% C
OR
RE
CT
FREE RECALL
“What are the warnings?”
![Page 24: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/24.jpg)
0102030405060708090
100
% C
OR
RE
CT
RECOGNITION
“Is _________ a warning?”
![Page 25: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/25.jpg)
0102030405060708090
100
% C
OR
RE
CT
RECOGNITION
“Is liver failure a warning?”
![Page 26: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/26.jpg)
0102030405060708090
100
% C
OR
RE
CT
RECOGNITION
“Is liver failure a warning?”
![Page 27: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/27.jpg)
OVERVIEW
0
20
40
60
80
100
% C
OR
RE
CT
Free Recall Recognition
![Page 28: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/28.jpg)
Does it matter?
YES
Warnings section location increased the ability to --remember the warning --recognize the warning
![Page 29: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/29.jpg)
Why?
1) Location
![Page 30: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/30.jpg)
Why?
1) Location
2) Chunking
![Page 31: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/31.jpg)
CONTRAINDICATIONS AND WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THESTART OF TREATMENT WITH ARAVA. ARAVA ISCONTRAINDICATED IN PREGNANT WOMEN, ORWOMEN OF CHILDBEARING POTENTIAL WHO ARENOT USING RELIABLE CONTRACEPTION. (SEECONTRAINDICATIONS AND WARNINGS.) PREGNANCYMUST BE AVOIDED DURING ARAVA TREATMENT ORPRIOR TO THE COMPLETION OF THE DRUGELIMINATION PROCEDURE AFTER ARAVATREATMENT. RARE BUT LIFE-THREATENING LIVERTOXICITY HAS BEEN REPORTED, INCLUDING ACUTELIVER FAILURE.
CHUNKING1
![Page 32: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/32.jpg)
CONTRAINDICATIONS AND WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THESTART OF TREATMENT WITH ARAVA. ARAVA ISCONTRAINDICATED IN PREGNANT WOMEN, ORWOMEN OF CHILDBEARING POTENTIAL WHO ARENOT USING RELIABLE CONTRACEPTION. (SEECONTRAINDICATIONS AND WARNINGS.) PREGNANCYMUST BE AVOIDED DURING ARAVA TREATMENT ORPRIOR TO THE COMPLETION OF THE DRUGELIMINATION PROCEDURE AFTER ARAVATREATMENT. RARE BUT LIFE-THREATENING LIVERTOXICITY HAS BEEN REPORTED, INCLUDING ACUTELIVER FAILURE.
CHUNKING
CONTRAINDICATIONS AND WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THESTART OF TREATMENT WITH ARAVA. ARAVA ISCONTRAINDICATED IN PREGNANT WOMEN, ORWOMEN OF CHILDBEARING POTENTIAL WHO ARENOT USING RELIABLE CONTRACEPTION. (SEECONTRAINDICATIONS AND WARNINGS.) PREGNANCYMUST BE AVOIDED DURING ARAVA TREATMENT ORPRIOR TO THE COMPLETION OF THE DRUGELIMINATION PROCEDURE AFTER ARAVATREATMENT.
RARE BUT LIFE-THREATENING LIVER TOXICITY HASBEEN REPORTED, INCLUDING ACUTE LIVERFAILURE.
1
2
![Page 33: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/33.jpg)
CHUNKING & CODING
CONTRAINDICATIONS AND WARNINGS PREGNANCY PREGNANCY MUST BE EXCLUDED BEFORE THE START OF TREATMENT WITH ARAVA. ARAVA IS CONTRAINDICATED IN PREGNANT WOMEN, OR WOMEN OF CHILDBEARING POTENTIAL WHO ARE NOT USING RELIABLE CONTRACEPTION. (SEE CONTRAINDICATIONS AND WARNINGS.) PREGNANCY MUST BE AVOIDED DURING ARAVA TREATMENT OR PRIOR TO THE COMPLETION OF THE DRUG ELIMINATION PROCEDURE AFTER ARAVA TREATMENT.
LIVER TOXICITY RARE BUT LIFE-THREATENING LIVER TOXICITY HAS BEEN REPORTED, INCLUDING ACUTE LIVER FAILURE.
3
![Page 34: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/34.jpg)
Virazole WARNINGS: USE OF AEROSOLIZED VIRAZOLE IN PATIENTS REQUIRING MECHANICAL VENTILATOR ASSISTANCE SHOULD BE UNDERTAKEN ONLY BY PHYSICIANS AND SUPPORT STAFF FAMILIAR WITH THE SPECIFIC VENTILATOR BEING USED AND THIS MODE OF ADMINISTRATION OF THE DRUG. STRICT ATTENTION MUST BE PAID TO PROCEDURES THAT HAVE BEEN SHOWN TO MINIMIZE THE ACCUMULATION OF DRUG PRECIPITATE, WHICH CAN RESULT IN MECHANICAL VENTILATOR DYSFUNCTION AND ASSOCIATED INCREASED PULMONARY PRESSURES (SEE WARNINGS ). SUDDEN DETERIORATION OF RESPIRATORY FUNCTION HAS BEEN ASSOCIATED WITH INITIATION OF AEROSOLIZED VIRAZOLE USE IN INFANTS. RESPIRATORY FUNCTION SHOULD BE CAREFULLY MONITORED DURING TREATMENT. IF INITIATION OF AEROSOLIZED VIRAZOLE TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS).VIRAZOLE IS NOT INDICATED FOR USE IN ADULTS. PHYSICIANS AND PATIENTS SHOULD BE AWARE THAT RIBAVIRIN HAS BEEN SHOWN TO PRODUCE TESTICULAR LESIONS IN RODENTS AND TO BE TERATOGENIC IN ALL ANIMAL SPECIES IN WHICH ADEQUATE STUDIES HAVE BEEN CONDUCTED (RODENTS AND RABBITS); (SEE CONTRAINDICATIONS ).
![Page 35: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/35.jpg)
DepakeneHEPATOTOXICITY: HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED IN PATIENTS RECEIVING VALPROIC ACID. EXPERIENCE HAS INDICATED THAT CHILDREN UNDER THE AGE OF TWO YEARS ARE AT A CONSIDERABLY INCREASED RISK OF DEVELOPING FATAL HEPATOTOXICITY, ESPECIALLY THOSE ON MULTIPLE ANTICONVULSANTS, THOSE WITH CONGENITAL METABOLIC DISORDERS, THOSE WITH SEVERE SEIZURE DISORDERS ACCOMPANIED BY MENTAL RETARDATION, AND THOSE WITH ORGANIC BRAIN DISEASE. WHEN DEPAKENE PRODUCTS ARE USED IN THIS PATIENT GROUP, THEY SHOULD BE USED WITH EXTREME CAUTION AND AS A SOLE AGENT. THE BENEFITS OF THERAPY SHOULD BE WEIGHED AGAINST THE RISKS. ABOVE THIS AGE GROUP, EXPERIENCE IN EPILEPSY HAS INDICATED THAT THE INCIDENCE OF FATAL HEPATOTOXICITY DECREASES CONSIDERABLY IN PROGRESSIVELY OLDER PATIENT GROUPS. THESE INCIDENTS USUALLY HAVE OCCURRED DURING THE FIRST SIX MONTHS OF TREATMENT. SERIOUS OR FATAL HEPATOTOXICITY MAY BE PRECEDED BY NON-SPECIFIC SYMPTOMS SUCH AS MALAISE, WEAKNESS, LETHARGY, FACIAL EDEMA, ANOREXIA, AND VOMITING. IN PATIENTS WITH EPILEPSY, A LOSS OF SEIZURE CONTROL MAY ALSO OCCUR. PATIENTS SHOULD BE MONITORED CLOSELY FOR APPEARANCE OF THESE SYMPTOMS. LIVER FUNCTION TESTS SHOULD BE PERFORMED PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER, ESPECIALLY DURING THE FIRST SIX MONTHS.
TERATOGENICITY: VALPROATE CAN PRODUCE TERATOGENIC EFFECTS SUCH AS NEURAL TUBE DEFECTS (E.G., SPINA BIFIDA). ACCORDINGLY, THE USE OF VALPROATE PRODUCTS IN WOMEN OF CHILDBEARING POTENTIAL REQUIRES THAT THE BENEFITS OF ITS USE BE WEIGHED AGAINST THE RISK OF INJURY TO THE FETUS.
PANCREATITIS: CASES OF LIFE-THREATENING PANCREATITIS HAVE BEEN REPORTED IN BOTH CHILDREN AND ADULTS RECEIVING VALPROATE. SOME OF THE CASES HAVE BEEN DESCRIBED AS HEMORRHAGIC WITH A RAPID PROGRESSION FROM INITIAL SYMPTOMS TO DEATH. CASES HAVE BEEN REPORTED SHORTLY AFTER INITIAL USE AS WELL AS AFTER SEVERAL YEARS OF USE. PATIENTS AND GUARDIANS SHOULD BE WARNED THAT ABDOMINAL PAIN, NAUSEA, VOMITING, AND/OR ANOREXIA CAN BE SYMPTOMS OF PANCREATITIS THAT REQUIRE PROMPT MEDICAL EVALUATION. IF PANCREATITIS IS DIAGNOSED, VALPROATE SHOULD ORDINARILY BE DISCONTINUED. ALTERNATIVE TREATMENT FOR THE UNDERLYING MEDICAL CONDITION SHOULD BE INITIATED AS CLINICALLY INDICATED. (See WARNINGS and PRECAUTIONS ).
![Page 36: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/36.jpg)
Experiments
chunked > unchunked
coded > uncoded
CHUNKING & CODING
![Page 37: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/37.jpg)
LEGIBILITY
![Page 38: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/38.jpg)
LEGIBILITYCONTRAINDICATIONS AND WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THESTART OF TREATMENT WITH ARAVA. ARAVA ISCONTRAINDICATED IN PREGNANT WOMEN, ORWOMEN OF CHILDBEARING POTENTIAL WHO ARENOT USING RELIABLE CONTRACEPTION. (SEECONTRAINDICATIONS AND WARNINGS.) PREGNANCYMUST BE AVOIDED DURING ARAVA TREATMENT ORPRIOR TO THE COMPLETION OF THE DRUGELIMINATION PROCEDURE AFTER ARAVATREATMENT. RARE BUT LIFE-THREATENING LIVERTOXICITY HAS BEEN REPORTED, INCLUDING ACUTELIVER FAILURE.
![Page 39: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/39.jpg)
LEGIBILITYCONTRAINDICATIONS AND WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THESTART OF TREATMENT WITH ARAVA. ARAVA ISCONTRAINDICATED IN PREGNANT WOMEN, ORWOMEN OF CHILDBEARING POTENTIAL WHO ARENOT USING RELIABLE CONTRACEPTION. (SEECONTRAINDICATIONS AND WARNINGS.) PREGNANCYMUST BE AVOIDED DURING ARAVA TREATMENT ORPRIOR TO THE COMPLETION OF THE DRUGELIMINATION PROCEDURE AFTER ARAVATREATMENT. RARE BUT LIFE-THREATENING LIVERTOXICITY HAS BEEN REPORTED, INCLUDING ACUTELIVER FAILURE.
CONTRAINDICATIONS AND WARNINGS
Pregnancy must be excluded before the start of treatment with Arava. ARAVA is contraindicated in pregnant women, or women of childbearing potential who are not using reliable contraception. (See Contraindications and Warnings.) Pregnancy must be avoided during Arava treatment or prior to the completion of the drug elimination procedure after Arava treatment. Rare but life-threatening liver toxicity has been reported, including acute liver failure.
![Page 40: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/40.jpg)
Imuran
WARNING Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS.
![Page 41: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/41.jpg)
READABILITY
![Page 42: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/42.jpg)
READABILITYCONTRAINDICATIONS AND WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THESTART OF TREATMENT WITH ARAVA. ARAVA ISCONTRAINDICATED IN PREGNANT WOMEN, ORWOMEN OF CHILDBEARING POTENTIAL WHO ARENOT USING RELIABLE CONTRACEPTION.PREGNANCY MUST BE AVOIDED DURING ARAVATREATMENT OR PRIOR TO THE COMPLETION OF THEDRUG ELIMINATION PROCEDURE AFTER ARAVATREATMENT.
# Words = 48# Sentences = 3
![Page 43: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/43.jpg)
READABILITYCONTRAINDICATIONS AND WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THESTART OF TREATMENT WITH ARAVA. ARAVA ISCONTRAINDICATED IN PREGNANT WOMEN, ORWOMEN OF CHILDBEARING POTENTIAL WHO ARENOT USING RELIABLE CONTRACEPTION.PREGNANCY MUST BE AVOIDED DURING ARAVATREATMENT OR PRIOR TO THE COMPLETION OF THEDRUG ELIMINATION PROCEDURE AFTER ARAVATREATMENT.
# Words = 48# Sentences = 3
Passives = 66%
Grade level = 12.0
![Page 44: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/44.jpg)
Readability Comprehensibility=
![Page 45: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/45.jpg)
Readability Comprehensibility=
--word familiarity
--sentence length
![Page 46: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/46.jpg)
Readability Comprehensibility=
--word familiarity
--sentence length
--# idea units
--syntactic complexity
--etc.
![Page 47: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/47.jpg)
LINGUISTIC STRUCTURE
![Page 48: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/48.jpg)
LINGUISTIC STRUCTURE
CONTRAINDICATIONS AND WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THE START OF TREATMENT WITH ARAVA.
ARAVA IS CONTRAINDICATED IN PREGNANT WOMEN, OR WOMEN OF CHILDBEARING POTENTIAL WHO ARE NOT USING RELIABLE CONTRACEPTION.
PREGNANCY MUST BE AVOIDED DURING ARAVA TREATMENT OR PRIOR TO THE COMPLETION OF THE DRUG ELIMINATION PROCEDURE AFTER ARAVA TREATMENT.
![Page 49: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/49.jpg)
“LARD”
![Page 50: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/50.jpg)
“LARD”
Lard--extra words in a sentence--make it hard to extract its basic meaning
![Page 51: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/51.jpg)
“LARD”
De-Larding Procedure
Rewrite each sentence using only: --essential prepositions --“full” verbs
Lard--extra words in a sentence--make it hard to extract its basic meaning
![Page 52: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/52.jpg)
“LARD”
De-Larding Procedure
Rewrite each sentence using only: --essential prepositions --“full” verbs
Lard--extra words in a sentence--make it hard to extract its basic meaning
ExampleThis sentence is in need of an action verb.
This sentence needs an action verb.
![Page 53: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/53.jpg)
“LARD”Sentence #1
OriginalPREGNANCY MUST BE EXCLUDED BEFORE THE START OF TREATMENT WITH ARAVA.
De-LardedEXCLUDE PREGNANCY BEFORE STARTING ARAVA TREATMENT.
![Page 54: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/54.jpg)
LARD FACTOR
CONTRAINDICATIONS AND WARNINGS
Exclude pregnancy before starting Arava treatment. Arava is contraindicated in pregnant women or women of childbearing potential who are not using reliable contraception. Avoid pregnancy during Arava treatment and after treatment (until completing the drug elimination procedure).
CONTRAINDICATIONS AND WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THE START OF TREATMENT WITH ARAVA. ARAVA IS CONTRAINDICATED IN PREGNANT WOMEN, OR WOMEN OF CHILDBEARING POTENTIAL WHO ARE NOT USING RELIABLE CONTRACEPTION. PREGNANCY MUST BE AVOIDED DUIRNG ARAVA TREATMENT OR PRIOR TO THE COMPLETION OF THE DRUG ELIMINATION PROCEDURE AFTER ARAVA TREATMENT.
Original
Revised
![Page 55: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/55.jpg)
LARD FACTOR
Compute the Lard Factor:
# Words (Original) – # Words (Revision) # Words (Original)
![Page 56: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/56.jpg)
LARD FACTOR
Compute the Lard Factor:
# Words (Original) – # Words (Revision) # Words (Original)
Lard Factor = .23
![Page 57: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/57.jpg)
OTHER EXPERIMENTS
- Readability- Attention- Comprehension- Memory- etc.
![Page 58: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/58.jpg)
OTHER EXPERIMENTS
- Readability- Attention- Comprehension- Memory- etc.
![Page 59: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/59.jpg)
OVERVIEW
0
20
40
60
80
100
% C
OR
RE
CT
Free Recall Recognition
![Page 60: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/60.jpg)
Why?
1) Location
2) Chunking
3) Legibility
4) Readability
5) Comprehensibility
6) etc…
![Page 61: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/61.jpg)
Effective -- when:
1) Legible --NOT ALL CAPITALS --serif font
2) Chunked --by type of warning
3) Coded --titles for chunks
BLACK BOX
![Page 62: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/62.jpg)
ADVANTAGES
Black Box Warnings
--Up front
--Box --visual --alerting
![Page 63: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/63.jpg)
ADVANTAGES
Black Box Warnings
--Up front
--Box --visual --alerting
--Context --all warnings --specific type
![Page 64: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/64.jpg)
Physically present
INFORMATION
![Page 65: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/65.jpg)
Physically present
Functionally absent
INFORMATION
![Page 66: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/66.jpg)
Evidence-Based Labeling
![Page 67: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/67.jpg)
Evidence-Based Labeling
1) Clinical trials
2) Post-market surveillance
![Page 68: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/68.jpg)
Evidence-Based Labeling
1) Clinical trials
2) Post-market surveillance
3) Label comprehension
![Page 69: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/69.jpg)
Evidence-Based Labeling
1) Clinical trials
2) Post-market surveillance
3) Label comprehension
![Page 70: RARE & SERIOUS EVENTS Label Comprehension Ruth S. Day Duke University ruthday@duke.edu FDA Arthritis Advisory Committee March 5, 2003](https://reader030.vdocuments.site/reader030/viewer/2022032414/56649eec5503460f94bfe97c/html5/thumbnails/70.jpg)
Evidence-Based Labeling
1) Clinical trials
2) Post-market surveillance
3) Label comprehension
0
10
20
30
40
50
% C
OR
RE
CT